<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176016</url>
  </required_header>
  <id_info>
    <org_study_id>OTS3050102</org_study_id>
    <nct_id>NCT04176016</nct_id>
  </id_info>
  <brief_title>Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma</brief_title>
  <official_title>Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoTherapy Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoTherapy Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and pharmacokinetics as well as the
      biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous
      administration of OTSA101-DTPA-90Y.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) and Biodistribution of OTSA101-DTPA-111In</measure>
    <time_frame>up to 72 hours post dosing</time_frame>
    <description>Concentration of OTSA101-DTPA in plasma and the distribution of OTSA101-DTPA in the body by imaging scan will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OTSA101-DTPA-111In</measure>
    <time_frame>up to 10 days post dosing</time_frame>
    <description>This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OTSA101-DTPA-90Y</measure>
    <time_frame>up to 6 weeks post dosing</time_frame>
    <description>This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed or Refractory Synovial Sarcoma</condition>
  <arm_group>
    <arm_group_label>Single Study Arm, no competitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTSA101-DTPA-111In</intervention_name>
    <description>single IV injection, 185MBq/body</description>
    <arm_group_label>Single Study Arm, no competitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTSA101-DTPA-90Y</intervention_name>
    <description>IV injection (max. 3 injections per patient), 1110MBq/body</description>
    <arm_group_label>Single Study Arm, no competitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a documented relapsed or refractory synovial sarcoma after standard
             chemotherapy

          2. Patients â‰¥18 years of age at the time of obtaining informed consent

          3. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
             0 or 1

          4. Patients with measurable lesion

          5. Patients not received any anti-malignancy agent or specified surgical intervention
             within 28 days or specified radiotherapy within 14 days prior to study registration.

          6. Patients without any clinically significant laboratory abnormality.

          7. Patients with adequate heart function as measured by echocardiography or multiple
             gated acquisition scan (MUGA).

          8. Patients with adequate pulmonary function as measured by pulmonary function tests.

          9. Patients who are either not of childbearing potential or who agree to use a
             contraception method during the study and for 12 months after the last dose of study
             drug

         10. Patients must be able to understand and be willing to sign a written informed consent

        Exclusion Criteria:

          1. Patients with documented concurrent malignancy.

          2. Patients with brain metastasis with clinical symptoms.

          3. Patients with any infection requiring systemic treatment.

          4. Patients with lung inflammation or pulmonary fibrosis.

          5. Patients with a known history of hypersensitivities to antibody agents or serum
             albumin agents.

          6. Patients with a known history of autoimmune diseases.

          7. Patients with myocardial infarction (MI) within 6 months prior to study registration.

          8. Patients with uncontrolled diseases.

          9. Patients with any disease requiring continuous systemic administration of steroids or
             immunosuppressants.

         10. Patients with evidence of active HBV, HCV or HIV infection.

         11. Pregnant or breastfeeding female patients, or female patients with suspected
             pregnancy.

         12. Patients who are participating any other investigational treatments during the study.

         13. Patients with psychiatric disorders and is considered to have difficulty to study
             participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>OncoTherapy Science</last_name>
    <phone>+81-44-820-8251</phone>
    <email>info@oncotherapy.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hironari Tamiya, M.D.</last_name>
      <phone>See Central Contact</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisuke Ae, M.D.</last_name>
      <email>keisuke.ae@jfcr.or.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kan Yonemori, M.D</last_name>
      <phone>See Central Contact</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

